SCHEMBL6955056

SCHEMBL6955056

Cc1nc(N2CCc3ccc([N+](=O)[O-])cc3CC2)c([N+](=O)[O-])c(=O)[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 4/20 0.40
ADRA2A P08913 2/20 0.40
TYMS P04818 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AURKA O14965 1/20 0.39
RPS6KB1 P23443 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
SLC29A1 Q99808 1/20 0.37
ROCK1 Q13464 1/20 0.37
HRH4 Q9H3N8 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
TDP2 O95551 1/20 0.36
PARP1 P09874 1/20 0.36
ADRA2B P18089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947740 0.88 TYMS (0.44) TYMSMAPTHTTRPS6KB1KMT2A
SCHEMBL6953047 0.88 MAPT (0.38) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL6950817 0.88 TYMS (0.44) TYMSLMNAMAPTMAPK1HTT
SCHEMBL6951360 0.86 LMNA (0.42) ALDH1A1LMNAMAPTHTTSMN1; SMN2
SCHEMBL6948442 0.85 CA1 (0.41) PNMTADRA2AALDH1A1LMNAMAPT
SCHEMBL6952830 0.83 RAB9A (0.47) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL6955100 0.82 MAPT (0.39) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL6435436 0.80 MAPT (0.35) ALDH1A1LMNAMAPTMAPK1HTT
SCHEMBL6948586 0.76 TYMS (0.44) TYMSALDH1A1LMNAMAPTMAPK1
SCHEMBL6952355 0.75 KMT2A (0.40) SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed